openPR Logo
Press release

Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028

05-19-2022 05:41 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Transdermal Patch Market, Dosage, Price and Clinical

Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028 Report Highlights:

* Research Methodology
* Global and Regional Transdermal Path Market Outlook
* Global Transdermal Patch Market Opportunity > USD 20 Billion
* Clinical Trials Insight By Company, Indication, Drug Molecule and Phase
* Comprehensive Insight On 60 Transdermal Patch Available Commercially
* Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase
* Transdermal Patch Dosage and Price Availability By Indication
* Competitive Landscape

Download Report:

The technological advancements in drug delivery have led to innovation of transdermal patches. The transdermal skin patches are articulated to deliver the active ingredients of drugs across skin into the systemic blood circulation in a continued or measured mode through diffusion. Apart from being convenient to patients and non-invasive, transdermal patches offer other advantages such as circumventing first-pass digestion and avoidance of gastric/enzymatic degradation. The transdermal patches are currently being commercialized as hassle-free, convenient, and durable products. These patches can be worn until seven days, depending on their therapeutic indication.

The promising response of transdermal patches in the global market has further surged the further research and development in this sector. For instance in 2019, US FDA has approved Secuado, which is the first transdermal patch to treat Schizophrenia. Further in 2021, Gedeon Richter UK has announced that it has become marketing authorization holder (MAH) for Evra, a once weekly contraception for women of fertile age and the only transdermal contraceptive patch licensed in UK. The rising product launches in the global market will have a positive impact on the growth of market.

The pipeline for global transdermal patches is crowded, which suggests positive future of these patches in forthcoming years. For instance, recent clinical trial from Starton Therapeutics showed the promising results of STAR-LLD continuous delivery transdermal patch containing lenalidomide in a non-GLP rabbit pharmacokinetic (PK) and skin irritation study. Moreover, US FDA has also assigned a Prescription Drug User Fee Act target date of March 11, 2022 for the new drug application for Aldarity (donepezil transdermal system) for the treatment of patients with dementia due to mild, moderate, and severe Alzheimer disease. Aldarity is a once weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. These rising trends will propel the growth of market during the forecast period.

Currently, vaccine segment doesn't have any transdermal patch showing that this area has lots of untapped opportunities for pharmaceutical companies. Several ongoing clinical trials are evaluating novel vaccine patch for influenza, HIV, COVID-19, and others. Recently in 2022, Institut Pasteur Korea (IPK) announced a research service agreement executed with Juvic Inc. for the joint development of microneedle based influenza vaccines. Merging Juvic's microneedle production technology and IPK's vaccine research and development capabilities, this collaboration is expected to facilitate the development of a microneedle influenza vaccine patch. Notably, the microneedle-based vaccine not only reduces the pain dramatically during vaccination but also can be distributed at room-temperature.

The global transdermal patch market is expected to witness high growth rates which is due to presence of key players and established healthcare infrastructure. Further beneficial government initiatives and an increase in the number of research partnerships are also expected to increase the market growth during the forecast period. Besides, high adoption rate of advance technologies is also expected to impel the growth of market in the region. As per our report findings, the global transdermal patch market is expected to surpass US$ 20 Billion by 2028.

US is currently dominating the global patch market due to presence of key transdermal drug delivery innovative companies and established healthcare infrastructure, beneficial government initiatives along with surge in the number of research partnership, increasing adoption of various strategies such as product innovation and increasing product launches and approval in this region. Apart from this, Europe has also emerged out to be potential market in last few years due to rising availability of products, increasing smoking population, and increasing awareness about the availability of patches in the market. The report global transdermal patch market provides detailed analysis on the currently market product along with their price, dosage, and generic availability. The insights into ongoing clinical trials by company, drug class, indication, and phase are also reported.


Neeraj Chawla
Research Head
Kuick Research

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028 here

News-ID: 2629954 • Views: 102

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases

More Releases for Transdermal

Global Transdermal Skin Patches Market | Global Transdermal Skin Patches Industr …
The transdermal skin patches market comprises of sales of transdermal skin patches products and connected services utilize to deliver medicine to the human body through patches. The Transdermal skin patches comprise the usage of adhesive patches made up of polymers that comprises drugs. The drug from such patches are absorbed into the body and ultimately into the blood stream disregarding the drug delivery through pill, or injections. According to the
Transdermal Patch Market Report 2018: Segmentation by Product (Fentanyl Transder …
Global Transdermal Patch market research report provides company profile for Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
US Transdermal Patch Market Outlook 2020 Report
“US Transdermal Patch Market Outlook 2020” Report Highlights: * US Transdermal Patch Market Overview * Generic & Branded Transdermal Patches * US Transdermal Patch Market: Value Chain Analysis * US Transdermal Patch Contract Manufacturing Organization * US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase * US Transdermal Patch Clinical Pipeline: 55 Patches * Majority Patches in Preclinical Phase: 23 Patches * Marketed Transdermal Patch Clinical Insight by Company & Indication * Marketed Transdermal Patches in
Therapeutic Landscape of Transdermal Drug Delivery Pipeline
Summary The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. GET SAMPLE REPORT @ Scope -
Transdermal Scopolamine Market Evolution / Developments
A new study by Transparency Market Research (TMR) indicates that Novartis AG, alone, contributed nearly 41.0% of the overall revenue of the global transdermal scopolamine market in 2016. Other two torch bearers in the market, namely, GlaxoSmithKline Plc and Baxter International Inc., commanded a cumulative share of 49.0% in the same year. Even though, the number of small players in the market is less, the degree of competition within the
Global Transdermal Absorption Patch Market Research Report
Latest industry research report on: Global Transdermal Absorption Patch Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Transdermal Absorption Patch industry. Complete Report Details @ This report splits